ABMD - Earnings call transcript Q1 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the First Quarter Fiscal Year 2019 ABIOMED, Incorporated Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time.

As a reminder, this conference is being recorded. I would now like to turn the conference over to your host for today Ingrid Goldberg, Director of Investor Relations.

begin. may You

Ingrid Goldberg

with morning President fiscal Good as Goldberg, to first format and call I'm ABIOMED's of and today's Chairman, Thank Executive for Chief Chief earnings and Financial conference follows. of Officer; here and ABIOMED XXXX Relations Trapp, Ingrid be Minogue, call. quarter ABIOMED's Investor President Vice you. Todd for welcome Mike and This will Director The is Officer.

then the Mike our turn will and highlights fiscal First, objectives. to from operational first strategic Minogue and key quarter discuss

Next, results Todd release. on Trapp will provide outlined details financial press in today's

We call then your questions. will open the for

and well I financial that Before and government risks capital matters, Each company's begin, presentation materially from relating regulation, in includes performance. remind statements subject would contained those I results differ as forward-looking everyone uncertainties is progress presentation in to that other and this as projected and statements. expenditures, this like to could to regulatory to litigation actual cause the about statement such clinical, forward-looking matters commercial

XXXX. Chairman, presentation speak the joining in for us. to these this ended information to report under Statements and Forward-Looking any on only heading the no Executive statements. date our to Chief release Minogue. Thank you uncertainties I'm XX-K ABIOMED's and obligation morning the and this of introduce press undertake we President of Officer, Form update presentation pleased for these or Mike Additional the in issued revise XX, now annual statements appears March this risks The regarding forward-looking and year

Michael R. Minogue

grew record grew our XX% we fiscal Japan, first adoption advanced which favorably million in in ABIOMED In and from outcomes $XXX reported quarter. with to this XX% everyone. QX, revenue. strong best revenue Impella PCI up year. each and XX% cardiogenic in and committed practices in improving ABIOMED Protected training, by and year another respectively. XX% patient European $X.X German driven QX, versus U.S. increased do prior revenue and experience. and In sharing XX%. XXXX. is real-world up utilization by of Impella was We Good to our revenue the increased start indications, million, delivered enhancements shock of Ingrid. morning, growth XX% derived Thanks, contributed a product sustainable through

patients our We have execution products, work STEMI with maintained and new Impella geographies. proud I and completed manufacturing indications to dedication new our our our also DTU of expanding Recovering and the disciplined capacity Hearts goals Saving on and while and safety study. feasibility increased strategic QX, and am new continued team's of for mission we hard FDA enrollment entire In adoption Lives.

For and like key will training to on FDA To today's our I time. training, start, study. and the call, initiatives and education strategic improve would adoption second, on two drive update topics: of to a clinical of and function data highlight outcomes; Impella Japan is an provide around I first, our adoption and

trained training we added globe new U.S. employees more nearly for employees including before recovery our employee new course with first commercial Board internal Recovery first and education records people and the quarter, our our training through We Training Heart educated or XX symposia heart at resources We global XX XXX in Massachusetts and physicians Danvers, Advisory first RP set hosting in in Tokyo distribution. and collaboration heart and our quarter course, Initiative Aachen, this on-site Impella headquarters meeting ever physician in the engagement. our German maximized meeting. Women's first Germany. institutes include over our hemodynamic This recovery kickoff than people QX and at across XXX commercial

patients, facilitate PCI investment the patients advanced Additionally, approximately coronary are XX community. programs dedicated Protected identify collaboration with disease conduct undertreated hospitals and translate heart team role. coordinators now there for quality Impella but patient and in heart allows focus a will appropriate coordinators of artery lowers improved costs. and not find XX we ejection our life health only recovery believe trained our to Increased will fraction on Protected with to improved outreach training We PCI help patients, survival increased native care help patient adoption outcomes. and overall and for also

Eric's and laser entrance. this Our blood of survival to an After life his and at Eric's story flow the children. has wife wife to The support, kids. benefit Michael Today, of recent recovery. husband, California, and returned the of CPR Center effective Gen Praga, and and recovered After Impella pain Eric's stents blocked multiple ventricle to shortness father percutaneous while Community Eric's was in three patient and implanted at open cost weaned major Eric feeling the emergency of occlusion to Fresno, story the the the highlights began his EF the continues the him that and hemodynamic promote concept. Medical Eric days Impella drove playing active LAD times. and confirmed to a XX-year-old his placed a removed. of two support months, performed six tag an XX% function hospital he left Eric Dr. with with chest reinforces the XXX% pump normal heart native to CP room solutions clinical heart. heart and staff heart artery. after Clovis both breath in and provide of shocked source collapsed coded active artery, catheterization enjoy heart A with an

studies data We and Eric. effectiveness continue patients for like to library build our clinical of cost

quarter, Impella cardiogenic such monitoring XX% implanted top This that quality best on call Multivariate Impella require IQ. Impella database volume. we the survival assurance AMI the be that cardiogenic as a PCI. confirms shock published and support This with shock protocols survival and Impella Impella XX,XXX rates with see hemodynamic analysis experience strategy, paper data first what the plus Journal pre in implantation at function sites a revealed we as survival of American patients was the Heart practices

this initiatives CSI to physician-led impacting like evidenced by accepted It recovery data awareness heart publication, National in world As by is independent community. the is published survival around U.S. see the clinical and real being the and exciting improving

Turning I June, to U.S., we team. In several eight sites XX in sites of management visited the have are outside of senior Japan, with in Japan opened the track new members our end year. to and on by the fiscal QX

government As sites opened Impella have we XX XXX of currently to-date. XX application. have the hospitals the July, a and total by approved Japanese of are committee downloaded

also for to visit and heart XXX success physician the Our both clear community it first native hemodynamic that multiple the nearly course physicians the and attendance, interventional appreciates surgery. representing had recovery. with remains support opportunity hospitals I clinical Tokyo a hemodynamic great both heart was in understands need cardiology in Japanese and and

most Additionally, Australia, we've in and, seeds Singapore, with patients are of Israel our treated To U.S., Hong but new centers in heart the countries. hospitals remain be been specific countries planting recovery select excellence priority, the in Kong, Japan forward Germany clear, moving we've India. and over year, recently, we in last and in

mid-June. I'm FDA enrollment feasibility to ahead we pleased schedule and announce in DTU our STEMI regulatory that to Moving study safety have for of completed our progress,

have the for a analysis reviewed and FDA to the timeline are submission with establish of We working data results. the and

FDA As FDA next We studies. the to the the opportunity we has review anticipate had submit protocol, dialog our the steering not August. in a until company with committee do more steps or and abstracts publish on

success heart field As release remains track in The of First After our are and we values are turn in will and to purpose our We QX, on targeting our balance will and our penetrate Heart the sheet and U.S. a we the property sustainable currently on like American November over their with XXXX of I a within standard-of-care of customers commitment I our fiscal the of secret their med-tech focused positioned QX. culture. publication Hearts Conference. and to create Patients result, shareholders we market we execution time. enable to the the Association success recovery commitment to over Todd. become for clinical advancing well improving for thank the the investment. at companies, Recovering In and our global closing, fastest recognize to growth focus and are to extensive portfolio. would remain intellectual execution strong standard-of-care for believe call profitable on our GAAP us one with for growing now outcomes as

Todd A. Trapp

performance and across Impella Mike, million all morning, $XXX Japanese launch. good first in with Germany, revenues U.S. of we versus the of XX% the driven million, utilization. increase million delivered versus continued revenue Thanks, everyone. saw increase last $XX patient quarter, an geographies. In XX% was in $XXX XX% by and and totaled increase year XX% last our or revenue to U.S., rose revenue XX% which the Outside year $XX to due million, up strength a

are our totaled controlled opened up million for We eight with sites. pleased quarter $X.X revenue in where rollout the as Japan new we

worldwide prior $X.X in our revenue fiscal QX, placed the end been roughly the U.S., quarter, have In the Impella X,XXX CP up X.X service versus of Impella XX% year. Additionally, million was at at the sites. the and

respectively. Additionally, the Impella X.X currently at RP and XXX XXX are and sites, the Impella

and prior for quarter slightly for Impella $XXX STEMI expect the manufacturing the the million, of ECP R&D product same for into and as support from and was the reorder prior in to continued geographic clinical as of quarter. increase rate the for units SmartAssist, and year. driven as inventory compared million, demand per due and as first X.X from was also expense mainly coming the future incremental costs combined the the XX.X% site to XX% to CP of reorder as for translated revenue X.X, in at by $XX initiatives. our strong and the to which growth The Average X.X cVAD Reorder year. Impella continued XX.X% studies. bulk be was RP during mix performance X.X enhancements well margin period see Registry XXX%. quarter. The a investments Impella increase rose new hospitals decrease U.S. well investments was to trial the in We X.X in a was QX Gross such BTR, the the quarters. approximately products to the

prior quarter platform which totaled Our lay expense clinical for increase or the will versus expansion compensation, efficient $XX launch technology, team. the $XX ability XX% the SG&A investments products our was programs, training million, to an growth. the Impella due long-term for commercial our groundwork make The variance of outcomes additional industry-leading and sustaining of incentive Japanese and in us of to year. improving gives million

these investments an operating to as to margin million income the QX Operating a stages still continue in XX% penetration. to the XX% XX%. which we are of grew will record translated was for market $XX company. We early of quarter, make in the The

more which investments. volume, offset higher to due was our points basis growth than XXX of expansion margin Our

We was are be this for believe versus our compensation XXX% awards, benefits net million tax half on up commercial the in pace relating track $X.XX share, half million company early investment We well to expense. $XX will the of the which to are of income XXXX. of GAAP share income a a faster advantageous programs and or of to recorded training reduction as the $X.XX educational $XX as share-based at excess in benefit per quarter or The second of XXXX. as saw of add per invest tax a QX into head employees we as first year. employee

the likely We see first quarter, our vesting a the on three smaller have expect to benefits the in will and largest schedule tax given quarters adjustments of year. impact we final excess

quarter remains $XXX sheet and balance marketable million of the cash securities. we and with ended Our debt-free

is practice standard settling to instead of vest in Our employee to when taxes pay withholding shares use the cash market. RSUs

utilized million we dilution reduce to cash As a QX, $XX result, compensation. from of stock in

to build priority for support initiatives continue cash property top to growth advantage. and Our our intellectual remains organic to

the Before I'd slowdown the year. typically physician the seasonality for remind slow year summertime a guidance, vacations. quarter to our fiscal turning cardiovascular like devices QX catheterization is in of to investors to full due and of labs

in confidence the growth With to summary, raising year. to given for be that expect QX. year low we all while continue first now range by markets $XXX our making outlook and X remainder end points strong revenue of XX% the As revenue In said, performance QX across and a slightly full are investments revenue be below the we objectives. the or to quarter year, $XXX in of of guidance the million up our to the for our and $XX the our expect million, in to we necessary the XX% execute geographies to support result, million

XXXX year the We the deliver well plan are to fiscal positioned for and remainder our beyond. of

the please open line questions. Sonia, now for

Operator

you. Thank

of Antalffy Danielle from comes Leerink question Partners. first Our

Your line is now open.

Danielle Antalffy

feasibility Hey, question also completing the STEMI good and much study. quarter so morning, on guys. for the good congrats Thanks taking and a

higher. Just or a quarter that QX. I to dip just because very up the been QX of the cognizant look wanted on this over quarterly at I be a sales second would QX Is even flat there different follow at to the to as actually that least slightly has three of question that be seasonal years, need in something seasonality and driving we last on model, sales?

Michael R. Minogue

In TCT in is in prior October. this September it's year. years, been

additional also So there the more of to prudent And advantage little training. taking we will bit be take slow more suggest are the of labs be And that People slightly vacations. then, it may time do it's course, are impact. a slower. for an because just of down to us

Danielle Antalffy

sense. lot a makes That it. Got of

on indications. the FDA Okay. guys And expanded for a you then question

I'm You expanded you us. from indications, if that Thanks start you're just talked do take inaugural directionally Initiative. quantify impact when so in Women's these can wondering yet, not whether at for you hold? see this seeing And about any if volumes to much. to the expect least help yet

Michael R. Minogue

some the in patients indications mildly cardiomyopathy from the high-risk PCI expanded and ejection benefit for Danielle, moderate also we are fraction believe shock. and we both and reduced seeing

at and up see for was in still to training was than of Incrementally, we're and levels the indications. was well expect new cardiomyopathy as And educating do stages everyone However, next more these continue the to years. previously. of higher early grow we to patients cardiomyopathy up these of and couple up myocarditis postpartum on

Danielle Antalffy

Helpful. Thank guys. you,

Michael R. Minogue

Thanks, Danielle.

Operator

Thank you.

question next comes Piper Matthew from O'Brien Our Jaffray. of

open. now Your is line

Matthew O'Brien

Great. questions. Thanks much for so taking the

attention Impella seen last on years. stack that of to I the we've start off could the one of think is lowest probably get over if was what's results, we the quarterly levels little two-year of going a couple bit

side talk of training you and can commercial U.S. back the that you that And exactly the if impact number? if a Mike, of in that a did then Todd, just would bit should Thanks. you're bit in things quarter that somewhat little about an half so, helpful? little things benefit the and on And be investments if that the could the talk you is that all that had and about how making on where Impella

Michael R. Minogue

Matt, talking about clarify utilization? comment could margin are the numbers, you talking on you or are U.S. you just the what's about –

Matthew O'Brien

Yeah.

this on while. year "slower, numbers several two-year at last past you it's and that we've a the then slower the if So look of a in revenue quarters, the still number versus one stack basis time growth – really seen good"

investors as So, the that little a bit in some from I might get attention you – down slowing U.S. know today think

talk impact fiscal training there about of it that QX. a if done like So bit was selling sounds the just of of was that you can Did And that. fair some amount during Impella in a U.S. efforts QX?

Michael R. Minogue

Sure.

in we QX So the grew numbers, grew QX to in year, the In XX% this ground of prior patients. in patients. XX% we just kind year,

growth So from prior is are and revenue two as From we're numbers well. the with rate, which net rate. obviously QX also bigger incrementally years And similar bigger to from we're a the much up up at from numbers. XX%, ago very QX significantly a

for think we're a So of I the bit an growth, seeing acceleration.

forecast we're higher training data to I And Our that progress prior continuing make than and is time. this do the year. on the year think

and clear be understand the the just numbers. I to wanted on So question

through This good the in also think or where get a On we to the second higher little for the people on we appropriate to quicker and operating have and prior we're opportunity certain margin investments and year we're we where QX trying cycle than the the more get on ahead make year tend because start year. we heads operating bit additional is in the of margin, got and the the got training – investments more fiscal QX, we've place a half. XXXX, in bring people first based in that's prior

else, Todd something clarify to else what us or let want know we answer. me can you if So know just let

Matthew O'Brien

Sure.

than just maybe year? It was field the had sounded your Just Is are in fiscal while done that like out a and a fair you've lot QX time reps done was last they selling as as not that specific. statement? a And training in of the to this much quick follow-up, there past. be more for

Michael R. Minogue

Yeah.

pretty So more It's based number number a did training. and we but the on about it trained Germany customers our people get this employees, We people ramp it good over and half. record see QX, to of U.S. We internal do record both some a the the on number of as before we numbers, acceleration own year more are internal the globe. people. second and again the an the and of and – We training growth, in positioning Japan, ahead trained the across get also feel a did it's record but in we place did the prior in

Matthew O'Brien

Fair enough. Thank you.

Operator

you. Thank

comes next Chris Our Guggenheim. question of Pasquale from

Your now is open. line

Christopher Pasquale

on the of just talked force expect and guys that XX a on U.S. for you investments terms pace strong and margin think higher changed another pace this comfortably about we follow-up you congrats making what Mike, you hiring how quarter. can means and of both in of about of line a reps the sustain the sales in level and going quarter top a expansion. investment Previously growth Thanks Has forward? are expansion should about we pace should training the

Michael R. Minogue

XX quarter. we to in changed XX. year, And Chris, to in the it then, the about a commercial X past, we've prior said people

was This XX. quarter, it

little schedule. of ahead So a

people, right profile. than didn't how two a In do it always we've we little we'll quarters, meet bit the the it's find years, if some look last at you XX. we our over If been, done more

glad QX. to hearing make and we does think simplify in part so it ahead we're you're the get us quarter, pace, much in since if we place training And out and the don't be change in productive. in QX I do but into summer any So now, people more

do don't we sessions to So, for the additional new later have in year. people

Christopher Pasquale

quick us the just on on And implants expected That's pipeline. update helpful. the Thanks. of one then ECP? Could you one timing first-in-man with

Michael R. Minogue

was and year. program both first in ECP marked. and fortunate CE now I was now spend on It's some that X.X for on and in are patients of passed the this time implants Germany hospitals are man. I X.X. June products, did the is reviews First-in-man some in see fiscal The to enough in the

excited we're Patients acute it technology. coming lot a heart is for literature of CE about for approach. and remind about There's new recovery walk XX currently invasive because can minimally a investors, both pump of benefits days. that And chronic our So up really to is get around. out all a the X.X unloading the marked patients. It's and

and pump people the peak of liters wean the pulsatility without can You it's to down, wean patients it provide these of risk X as flow. off than going more It flow. does having you retrograde give

of a of So, and be ventricle. really that sternotomy without pump it's out a put the coring requiring new type can left in

So both, the X PCI. as French do ECP platform a could for which Protected be the and X.X liters we're on excited ideal to for Impella pump, a X

Christopher Pasquale

Thanks.

Operator

Thank you.

comes of from question next Jefferies. Our Raj Denhoy

line open. is Your

Anthony Petrone

with couple Congratulations questions start, I'm in good this Hi, of going another a Anthony for Mike, is quarter. on Raj. there. Japan, just to

in then expansion hospitals this accelerate you terms just Japan? long million So, take much going have do the will And you I'm in for But the $X.X tracking year. to sort year. into in rollout significantly controlled rollout this line expectation the plays phase is looks is wondering million out How like controlled how $XX our to the think place. and of with of the it that very in

How plays versus, Thanks. follow-up. in So, high then low out terms stack And have do over medium users how of users this think a basis? those time? say, and center-by-center on users I will you a

Michael R. Minogue

Anthony, we our for are on first year full track Japan. in

places confident that centers, is So good most all outcomes protocols about feel important, very as going opening getting the this year be patients. and, in we've said, to we're putting for We our there. right

would as We be following And at the long the that quarters going as year, we some that we'll process and into with what outcomes, growing This more pacing pace. getting the Impella year to we much two go and or approach year good and extent are we've Impella be this right three, have go. start with could we're to pattern three as faster to CP the done with RP. what done matched at we've a said,

the to into like we trying launch model and, we're So Japan again, directly.

So government unloading understands the is therapy. that recovery heart and Japanese a new

CP they along the of Impella of the that the trust and to for and X.X. thinking the XX next great submitting company, want the have make years the that of future, be we sure a then integrity the will the And we being Japan reputation, terms RP, the We because care. standard we're about in and

Anthony Petrone

just the sticking with theme there. Very one helpful. India, have congratulations The And the STEMI. today on O-U.S. and follow-up on announcement I

Just there is this then, X-day markets you rollout have time? then thoughts a total you why country of, then outcome as in but time X- endpoints, India over endpoints size as this we of a and two secondary European for frames have several on a XX-day look later to year, those on a the your mass, and measure. measure primary percent infarct STEMI, what and ahead readout just at on other And say, plans are

those One all-cause of mortality. is

across a of but primary will endpoints secondary drive well. think resonate of in So, there's all will you Clearly, what do some those there the as endpoints? lot attention,

going STEMI? be when So, you interesting read what Thanks. to on most is that get

Michael R. Minogue

Sure.

and India the prioritization. the on first question So was

drive help for commented in as government I U.S., still there relationship will for countries. reimbursement the There seeds interest to those That's work excellence focus in we priority. sites are establish recovery. heart therapy remarks, certain U.S., with as outside is prepared the – There a with to continue our we Germany centers to and are heart main but planting out of So our and Japan. my the is

and that's and this new concept has a has So Germany recognized is U.S. it's has what recognized. what FDA recognized, the Japan

means recommending it cascade commercial benefit in that to there's creates think a any formula. preconditioning way. before It to bring and that researchers this the parts partners think which other to and utilize is together. right best to technology country. work the do of and people were On they before benefits that And demand a risking way is We're governments where apoptosis keep because reduce we've study that somewhat within reduces we continue XX they the unloading. the have to benefit then unload, the means entered done does radical that because opinion muscle for it events study with during is that to leaders was question we opening work minutes up we'll the second two – That's is was The process, to the the today. safety then the way follow and procedure precondition infarct heart matches and and that the unloading STEMI, pivotal your dying we were so oxygen the of that does Europe isn't from the what we is it we left something not the get after size. the This can a One the we because which key revascularization study myocardium on we what done a it on the we've can feasibility And concept unloading or proven find asking blockage. that of myocardium. and ventricle,

to a studies chance the have information. FDA a play. the that we those things So I has about to we intended always our do talk strict review until don't it. to integrity as a go policy were pivotal, the of academic two We've There also is mentioned, but in

be or about Before or the recovery The it came acute investors the one JACC. they announced, of to advance more will the lead promotes read to a are Kapur It's it has would solid left infarction. if understand before And there's And kept reperfusion called publication note ventricular thing Dr. myocardial that science. after unloading just is one science confidential. want excited behind I to functional the this, authors. out in be to reference we continue for

do leave a of about excited explain will So patients it within does alive what heart hospital people trying heart failure you're we're what but years certainly is heart failure. attacks, be asking lot five about. is have for prevent to what that But most XX% of the

to So, the that's more gets and that information publication the on as come released.

Anthony Petrone

again. Thanks

Operator

you. Thank

from next Bruce Nudell SunTrust. comes of Our question

Your line is now open.

Bruce M. Nudell

Hi. Mike, trial, just the STEMIs PCI the question. cardiogenic Thanks XXX,XXX on for with taking shock. without counted STEMI we

into onset, Anthony's of results pivotal on you it's get heart longer you Just to the of available, you significant short-term those you question. once think a cetera, going Do measures adoption kind outcomes the and determinative? the term do feel – have that be are follow-up are to drive to will et or to enough or failure going be

Michael R. Minogue

cardiac then can Bruce, comment And first two with in effect infarct but unfortunately heart they you an trial, MRI take I or obviously for And into there's that in an see do what potentially the is going XX with starting patients long-term that the year the they're XX% in poor the say specifically the believe days. the failure. pivotal and can't is MRI, concept year. benefits, – first five very benefits. on in be And we can term I benefit can seen zone short in

heart. think referenced, There's I it can the things per talk we does see. of genes the if cardioprotective also So there's you the in of associated can you the paper about the – response test expression things around some with you

ways other patient analyze that infarct at what's area. has look when So there's unloading you're and a to a large happening

I the and both So think to term patients. short question, be there to advance, your and they excited will benefits see to show longer signal we're again to these signs

Bruce M. Nudell

And my follow-up is on cardiogenic shock.

you to are are people eye-opening get how have of significant Maybe to And mechanical counted very cardiogenic regards a is are support quarter those and You're where showing a the compelling great community pumps. balloon pretty kind usage We the With of momentum XXX,XXX most that cited, XX% clinical in in the admissions. space. AHJ those where you shock? results article survivorship? much

Michael R. Minogue

I think it is eye-opening.

think I by at was physician a call TCT to arms year experts. last there why the that's

put XX-plus Around a talking the a and one gets and we're not groups own about about multiple to live country a endorsed of talking in less ICU, in heart. their which and out go that protocol But talking the some about there's place. home population there's So again only X-year-old we're not hospitals, young we're have there. with

for of not can probably so, patient, the exist one it's the all that's the most outcomes of in we that And one but highest cost only med-tech. savings a produce significant

they they're devices, multiple within with that the die response patients about then followed the implantable time XX organ at autoimmune therapy. talking X again based capable, surgeries, if followed not you're time going and they on immediately, die it by potentially all to by they over to As die to a transplant years are a over

this the unloading comes and a demanded protocols, that the science I change these that people practices impact, out see there. The is more will standard and by the best have of more the communities can So these around the profound an benefits think care. in be more out it

Bruce M. Nudell

Thanks so much.

Michael R. Minogue

Bruce. Thanks,

Operator

Thank you.

Our Sachs. next question from comes Goldman of Ro Isaac

is Your now open. line

Isaac Ro

Good morning. Thanks.

consider about Just one the versus trend force clinical programs side. from of we R&D, between the Todd, think you of SG&A sequential me on if help the sales the you some through some could development programs. expense talked us if on wondering and

the improvement we're for the guidance the margin sequential that in You year. guys year rest margin reiterated and of expecting for so a op

between SG&A to make sure you. discrete the we items R&D considered within Thank wanted Just get that? and

Todd A. Trapp

sure. Yeah,

again, in a we Mike of of the And So the volume And as in which Japan. lay the I we right it did investments. terms by hiring it we'll and relates Germany some first than believe U.S., to of XX%, offsets part continue training that we also was a And mentioned, more as QX groundwork commercial firmly at the And our again driven in the to of and some as half investments in for our are investments mentioned the the educational increase for these XX% thing do second up QX, team margins were and and quarter accelerate programs. record. stepped the to performance. just

of And relates probably amounts level it should those year. versus in similar second As QX. in to half R&D off spend expect SG&A, I to this the of the kind in

with in as in know, expanded evidenced out. you also and Registry last cVAD products have has new great BTR continue to ECP shock, IQ cardiogenic this what So both our from look and us for an products expectations, exciting like an been saw for X.X and of And pipeline data our indications RD&E a high-risk foundation the PCI we we build as obtain to to coming database. quarter we and the data

So going I off. some see investments in big to of variable – think half, at when year and you think be high the is leveling second about the contribution a the to the convert the variable that margin incremental will half first going volume half/second we're of drivers,

Isaac Ro

guys. Thank Understood. you,

Operator

you. Thank

question Jayson Our Raymond James. of from next comes Bedford

Your now open. line is

Jayson T. Bedford

morning. Good

sites shock what Just in two percent related Thanks. Registry questions. in How the And protocols or quick your cVAD where your converting then to of are you many shock centers have place? protocol?

Michael R. Minogue

say Jayson, that that protocols hospitals adhered around XXX have we we have in place to. think would we are more

it As is we though the difficult. point to out always in compliance that certain somewhat hospitals XXX%

a but the have we people levels comfort of the have different the excited different Database from who in for can with see You scale have on IQ to make in physicians outcomes and also improvement protocols. have does it, We've we're protocols you these all that And sites. different a have place. seen XXX-plus in our it difference think broad hospital or physicians, of groups

and key the Database fraction native survival higher recovery with or is, of So improve they their of almost discharged be increase. they lower survivors have net a for a survival, have the average heart. is and whether to And the of continues opportunity our the survival effect do all ejection to do they one their the points IQ

Registry, now It we've our nested inside cVAD study. post-market of FDA the remember, a and use Registry We prospective with study. FDA one-year cVAD this it is follow-up. definitions For is

that, track all So, footprint. and that under further benchmark it we hospitals, to the our benefit and continuing we'll continue at do information look are to practices at products all best patients, all us regulatory to gives also

with we're the to excited those data. to care more advance continue with to So, work scrutiny centers over

Jayson T. Bedford

you. Thank

Operator

you. Thank

Blair. next of Our from comes question William Kaczor Margaret

open. now is line Your

Margaret M. Kaczor

for folks. taking morning, the Good questions. Hey. Thanks

to how conversations longer I higher one use? has so far? me, more color finding (XX:XX) treat the been first physicians have you but current why So very don't any mean, flow Are can you days, with that is rate from more about actually it's early hospitals X.X I you on and know give it allowing it's and uptake patients?

Michael R. Minogue

question. for thanks Margaret, the

We Class hospitals, have personally positive that a Germany, that both have a it There to limited research and In allow to I and heart are a been hospitals, support. seen it. number does very of because been sites of be patients lot patients. III. around the on have I've failure that has VAD there's patients have flow feedback, full in put these

unloading a has and and of paper research lot which research inflammatory believe potential that period Uriel, over of inflammatory There's there's reduction ventricle, there's cell the in looking very ability drugs. the in in is patients, of and on Dr. heart Cardiology – who sick benefits of of product. College that create work is support failures, Journal there's is more heart failure, chronic author failure. mechanical can heart this it's main for improvement there and patients chronic before become the the which you treated more the of of a these There – organ showing lot also been but can that again come do out become that an in that of for autoimmune interest therapy, Some patients these with to recovery. that is out where in unloading Japan providing have But to just response, potential the that. in be also physicians in cardiologist patients they're heart American response to The there's Germany, have may now of lot IV Nir spot there's failure suppression another these extended is a by sweet a can stem shows the also failure are interest that and can having a a Chicago, at science of a in have left came lot some and and have the some more reduce they unloading they extremely of or and unloading, us is to Class

to We but easier know collect it's pump. an believe, we higher that have the right a improvement it's the just to way, the better implant it X.X, to ensure safe, it's we and, continue off flow, has data it's

more as we that continue to on give collect data. we'll details So, clinical

Margaret M. Kaczor

to-date? have a And that launch rollout And as have you in then controlled broader you learned the right. Thanks. just on phase All Are RP, begun what follow-up guys or towards push the procedures? rollout? biventricular more from you the still to a moving to

Michael R. Minogue

centers in we to quarter. the more now mode. of launch a to add continuing full a RP, We're XX XX For are

on itself, it multiple things the remember learning are has product but patients. of We types

some So, failed patients are transplant.

having shocks. are Some biventricular

Some are having RV infarcts.

the And comes and protocol, team a approach back in so, making put timely. have a to make always it device heart having is sure sure we

Operator

Stanley. from you. our comes Morgan Lewis next Thank David question And of

line Your open. now is

Jaypreet S Chadha

Jay utilization This then hospitals talk in the Chadha morning. about place you quick rates between is the without difference hospitals with Can David Good just growth Lewis. for one have And I versus shock protocols in place? in protocols or in follow-up.

Michael R. Minogue

biased believe Protected this creating and volume. of things that the are we coordinators, that recovery energy would more they're self-selecting for PCI are because have place around have heart places We in obviously that volume higher also We we and do more is it what bit resources, survey of but practices a get a call getting centers excellence. do those doing higher sites best

Jaypreet S Chadha

And would could commercialization know you. still what or be? pathway you the for the for Impella about talk timeline opportunity? that to market I Thank and it's early Okay. BTR,

Michael R. Minogue

a be permanent It's pump longer that an artery. implanted The axial the Impella BTR will for term through pump. everyone axillary also is

it and an design new So purge-less discharge sensor. have for all is flows, VAD with to up intended have year we platform our a to products new full the a the console. And it's go will optical includes

signs the ideal we but and lot outcomes, patient. will that through And of new will console the cardiac go now, time patients and hospital's the Wi be to outcomes which something called be hospitals them to help connected able us only on, into not in of of managing for a which ability get new life new more to monitoring these right to And hospitals Impella we eight information weaning Connect transmits for while and at real around cloud I algorithms patients gives world that are have running. time, the power which opportunity a offer ultimately improve a better be ICU. we we and real think quality there's stay reduce when So improve on the The get length the in show means them them. the patients Fi productive, device the help pump in great is

Operator

back I Thank like conclude turn and over remarks. for call session. And would you. gentlemen, Minogue this our ladies to question-and-answer Michael the now further to does any

Michael R. Minogue

everyone, today. Thank time you, your for

questions, day. follow-up reach to any free please great out. have Have you a If feel

Operator

Ladies participating and program. gentlemen, in for thank today's This you conference. today's concludes

Everyone, great disconnect. day. You may all have a

Abiomed (ABMD) 26 Jul 182019 Q1 Earnings call transcript